amitriptyline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antidepressants, dibenzo[a,d]cycloheptane or cyclopheptene derivatives	180	50-48-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: amitriptyline amitriprolidine amitriptylin damitriptyline amitriptyline hydrochloride amitryptiline amitryptiline hydrochloride amitriptyline HCl amitryptiline HCl

Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. Molecular weight: 277.41 Formula: C20H23N CLOGP: 4.85 LIPINSKI: 0 HAC: 1 HDO: 0 TPSA: 3.24 ALOGS: -4.79 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
75	mg	O
75	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1000 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	15.45 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	48 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	8.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	6.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.07 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	17 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 7, 1961	FDA	ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	3849.17	44.68	922	3810	20112	2333241
Toxicity to various agents	3251.05	44.68	882	3850	31872	2321481
Drug abuse	1122.97	44.68	313	4419	11713	2341640
Overdose	1104.60	44.68	346	4386	19561	2333792
Cardiac arrest	1095.71	44.68	322	4410	14608	2338745
Cardio-respiratory arrest	958.74	44.68	261	4471	8885	2344468
Respiratory arrest	954.50	44.68	240	4492	5938	2347415
Intentional overdose	710.71	44.68	217	4515	11104	2342249
Death	544.84	44.68	314	4418	81154	2272199
Coma	531.25	44.68	165	4567	8891	2344462
Drug hypersensitivity	479.98	44.68	240	4492	46403	2306950
Electrocardiogram QRS complex prolonged	434.48	44.68	92	4640	1010	2352343
Suicide attempt	428.48	44.68	148	4584	11134	2342219
Poisoning	426.47	44.68	108	4624	2712	2350641
Serotonin syndrome	416.33	44.68	111	4621	3429	2349924
Hypotension	411.79	44.68	193	4539	32243	2321110
Electrocardiogram QT prolonged	406.45	44.68	130	4602	7684	2345669
Drug interaction	402.74	44.68	184	4548	28979	2324374
Drug ineffective	391.49	44.68	277	4455	101347	2252006
Somnolence	387.70	44.68	168	4564	23317	2330036
Loss of consciousness	351.79	44.68	147	4585	18620	2334733
Depressed level of consciousness	328.58	44.68	110	4622	7494	2345859
Intentional product misuse	319.83	44.68	114	4618	9375	2343978
Confusional state	296.49	44.68	141	4591	24203	2329150
Pain	232.95	44.68	167	4565	61690	2291663
Tachycardia	227.26	44.68	104	4628	16305	2337048
Agitation	221.66	44.68	91	4641	10960	2342393
Anticholinergic syndrome	220.35	44.68	42	4690	254	2353099
Fibromyalgia	217.88	44.68	66	4666	3234	2350119
Delirium	215.31	44.68	73	4659	5150	2348203
Fall	209.56	44.68	141	4591	46958	2306395
Suicidal ideation	207.83	44.68	87	4645	11000	2342353
Cognitive disorder	205.39	44.68	71	4661	5310	2348043
Seizure	204.59	44.68	110	4622	24356	2328997
Bradycardia	202.90	44.68	83	4649	9898	2343455
Dizziness	199.45	44.68	149	4583	58516	2294837
Respiratory depression	198.91	44.68	56	4676	2114	2351239
Shock	193.08	44.68	63	4669	3941	2349412
Mydriasis	188.66	44.68	54	4678	2165	2351188
Sinus tachycardia	187.77	44.68	59	4673	3266	2350087
Accidental overdose	185.48	44.68	61	4671	3911	2349442
Dry mouth	182.74	44.68	73	4659	8180	2345173
Synovial fluid analysis	182.52	44.68	26	4706	5	2353348
Rheumatoid arthritis	176.74	44.68	92	4640	19048	2334305
Ventricular tachycardia	176.59	44.68	55	4677	2956	2350397
Pulseless electrical activity	163.78	44.68	41	4691	974	2352379
Vomiting	161.09	44.68	143	4589	71459	2281894
Tenosynovitis stenosans	157.47	44.68	28	4704	107	2353246
Depression	146.25	44.68	93	4639	28039	2325314
Musculoskeletal stiffness	145.83	44.68	70	4662	12177	2341176
Circulatory collapse	141.56	44.68	49	4683	3671	2349682
Scleritis	140.24	44.68	29	4703	279	2353074
Hyponatraemia	137.26	44.68	69	4663	13256	2340097
Coma scale abnormal	136.76	44.68	34	4698	784	2352569
Metabolic acidosis	136.00	44.68	54	4678	5944	2347409
Impaired work ability	135.88	44.68	40	4692	1770	2351583
Arthralgia	131.08	44.68	113	4619	54172	2299181
Insomnia	130.89	44.68	84	4648	25703	2327650
Crepitations	128.17	44.68	31	4701	635	2352718
Poisoning deliberate	119.46	44.68	33	4699	1158	2352195
Joint effusion	117.21	44.68	33	4699	1243	2352110
Hallucination, visual	116.27	44.68	40	4692	2939	2350414
Muscle spasms	116.25	44.68	73	4659	21493	2331860
Feeling jittery	116.22	44.68	36	4696	1896	2351457
Cushingoid	115.37	44.68	28	4704	582	2352771
Rheumatoid nodule	115.01	44.68	28	4704	590	2352763
Nausea	110.94	44.68	145	4587	112044	2241309
Synovial cyst	110.28	44.68	29	4703	841	2352512
Generalised tonic-clonic seizure	110.15	44.68	45	4687	5327	2348026
Drug withdrawal syndrome	109.44	44.68	48	4684	6773	2346580
Pleuritic pain	108.52	44.68	27	4705	624	2352729
Drug intolerance	107.00	44.68	59	4673	13658	2339695
Pain in extremity	105.50	44.68	90	4642	42450	2310903
Bursitis	104.11	44.68	33	4699	1875	2351478
Sacroiliitis	102.09	44.68	22	4710	262	2353091
Akathisia	99.87	44.68	31	4701	1643	2351710
Tenderness	99.81	44.68	32	4700	1886	2351467
Tremor	99.11	44.68	65	4667	20596	2332757
Exposure via ingestion	98.60	44.68	26	4706	762	2352591
Orthostatic hypotension	98.32	44.68	35	4697	2844	2350509
Malaise	97.73	44.68	97	4635	55488	2297865
Dyspnoea	97.36	44.68	114	4618	78619	2274734
Sedation	96.67	44.68	36	4696	3326	2350027
Myoclonus	95.57	44.68	33	4699	2450	2350903
Brain injury	94.64	44.68	26	4706	893	2352460
Constipation	94.00	44.68	64	4668	21565	2331788
Balance disorder	93.11	44.68	48	4684	9699	2343654
Heart rate increased	92.78	44.68	50	4682	11055	2342298
Hyperhidrosis	92.72	44.68	56	4676	15366	2337987
Psychotic disorder	91.85	44.68	38	4694	4641	2348712
Musculoskeletal pain	91.14	44.68	49	4683	10781	2342572
Dry eye	90.98	44.68	36	4696	3920	2349433
Unresponsive to stimuli	90.34	44.68	38	4694	4838	2348515
Eye pain	90.23	44.68	38	4694	4853	2348500
Flank pain	89.61	44.68	28	4704	1517	2351836
Restlessness	89.38	44.68	37	4695	4526	2348827
Conjunctivitis	89.00	44.68	31	4701	2362	2350991
Respiratory failure	88.82	44.68	52	4680	13476	2339877
Haemodynamic instability	88.23	44.68	26	4706	1153	2352200
Condition aggravated	88.22	44.68	72	4660	31907	2321446
Pruritus	88.16	44.68	82	4650	43258	2310095
Cardiogenic shock	87.78	44.68	31	4701	2460	2350893
Atelectasis	86.95	44.68	29	4703	1936	2351417
Antinuclear antibody positive	85.99	44.68	25	4707	1057	2352296
Headache	85.91	44.68	108	4624	80071	2273282
Mental status changes	85.40	44.68	38	4694	5544	2347809
Neuroleptic malignant syndrome	85.34	44.68	29	4703	2051	2351302
Drug dependence	85.33	44.68	32	4700	3013	2350340
Aggression	84.35	44.68	36	4696	4750	2348603
Ulcer	84.20	44.68	28	4704	1852	2351501
Nodule	83.41	44.68	29	4703	2197	2351156
Pneumonia	82.87	44.68	84	4648	49212	2304141
Somatic symptom disorder	82.72	44.68	19	4713	308	2353045
Treatment noncompliance	82.50	44.68	37	4695	5497	2347856
Lung disorder	81.51	44.68	38	4694	6174	2347179
Dystonia	79.96	44.68	28	4704	2166	2351187
Photophobia	78.80	44.68	28	4704	2261	2351092
Psychotic disorder due to a general medical condition	77.68	44.68	13	4719	31	2353322
Abdominal pain	77.62	44.68	69	4663	34305	2319048
Hallucination	77.44	44.68	40	4692	8108	2345245
Swelling face	77.21	44.68	42	4690	9451	2343902
Arrhythmia	76.38	44.68	36	4696	5992	2347361
Acute respiratory distress syndrome	75.84	44.68	30	4702	3262	2350091
Disturbance in attention	75.27	44.68	35	4697	5650	2347703
Cardiotoxicity	73.99	44.68	23	4709	1224	2352129
Feeling abnormal	73.34	44.68	57	4675	23524	2329829
Maternal exposure during pregnancy	71.81	44.68	47	4685	14816	2338537
Atrioventricular block first degree	70.93	44.68	21	4711	946	2352407
Product use in unapproved indication	70.74	44.68	42	4690	11158	2342195
Anxiety	70.40	44.68	61	4671	29298	2324055
Pulmonary eosinophilia	70.10	44.68	14	4718	111	2353242
Erythema	70.08	44.68	57	4675	25102	2328251
Joint swelling	68.86	44.68	48	4684	16771	2336582
Dysarthria	68.85	44.68	34	4698	6268	2347085
Disorientation	68.49	44.68	34	4698	6338	2347015
Dyskinesia	68.15	44.68	31	4701	4758	2348595
Speech disorder	68.03	44.68	34	4698	6430	2346923
Hyperreflexia	67.99	44.68	20	4712	881	2352472
Urinary retention	65.99	44.68	28	4704	3639	2349714
Hypertension	65.90	44.68	57	4675	27304	2326049
Exposure during pregnancy	65.78	44.68	55	4677	25164	2328189
Wheezing	65.48	44.68	33	4699	6351	2347002
Withdrawal syndrome	65.14	44.68	27	4705	3310	2350043
Visual impairment	63.77	44.68	40	4692	11715	2341638
Pyrexia	63.29	44.68	76	4656	53632	2299721
Bradypnoea	62.42	44.68	16	4716	418	2352935
Thrombosis	62.24	44.68	36	4696	9108	2344245
Accidental death	62.14	44.68	15	4717	304	2353049
Rash	61.72	44.68	79	4653	59479	2293874
Treatment failure	61.57	44.68	33	4699	7206	2346147
Paraesthesia	61.41	44.68	50	4682	22038	2331315
Infection	61.36	44.68	46	4686	17983	2335370
Myofascial pain syndrome	59.55	44.68	13	4719	165	2353188
Respiratory rate decreased	57.99	44.68	16	4716	558	2352795
Emotional disorder	57.81	44.68	22	4710	2155	2351198
Aspiration	57.52	44.68	20	4712	1514	2351839
Eye irritation	57.22	44.68	25	4707	3487	2349866
Neoplasm malignant	57.18	44.68	28	4704	5065	2348288
Ocular hyperaemia	56.90	44.68	26	4706	4030	2349323
Therapeutic product effect decreased	56.74	44.68	36	4696	10753	2342600
Amnesia	55.96	44.68	31	4701	7222	2346131
Gastrointestinal disorder	55.15	44.68	33	4699	8884	2344469
Myalgia	54.94	44.68	48	4684	23285	2330068
Hypoglycaemia	54.31	44.68	32	4700	8375	2344978
Fatigue	53.52	44.68	89	4643	84784	2268569
Acute kidney injury	52.87	44.68	51	4681	28071	2325282
Mood altered	52.85	44.68	22	4710	2724	2350629
Pneumonia aspiration	52.53	44.68	24	4708	3718	2349635
Clonus	52.50	44.68	15	4717	595	2352758
Gait disturbance	52.31	44.68	46	4686	22499	2330854
Blood pH decreased	51.05	44.68	14	4718	477	2352876
Sleep disorder	50.78	44.68	28	4704	6461	2346892
Muscular weakness	50.65	44.68	38	4694	14859	2338494
Asthenia	49.75	44.68	63	4669	46863	2306490
Swelling	49.66	44.68	39	4693	16311	2337042
Fracture	49.62	44.68	21	4711	2710	2350643
Stubbornness	48.44	44.68	8	4724	17	2353336
Delusion	48.19	44.68	19	4713	2046	2351307
Back pain	47.79	44.68	51	4681	31608	2321745
Migraine	47.35	44.68	32	4700	10621	2342732
Ventricular fibrillation	47.01	44.68	19	4713	2182	2351171
Immune thrombocytopenic purpura	46.51	44.68	17	4715	1487	2351866
Hypoaesthesia	46.40	44.68	41	4691	20174	2333179
Foetal death	46.05	44.68	18	4714	1894	2351459
Interstitial lung disease	45.95	44.68	28	4704	7784	2345569
Pulse absent	45.81	44.68	15	4717	944	2352409
Movement disorder	45.64	44.68	20	4712	2808	2350545
Asthma	45.60	44.68	32	4700	11282	2342071
Therapeutic product effect incomplete	45.30	44.68	31	4701	10500	2342853
Peripheral swelling	45.06	44.68	38	4694	17559	2335794
Status epilepticus	44.84	44.68	19	4713	2459	2350894

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	1698.35	50.65	503	2023	28638	1715617
Completed suicide	1533.32	50.65	411	2115	15901	1728354
Overdose	699.60	50.65	227	2299	16474	1727781
Drug abuse	654.64	50.65	206	2320	13483	1730772
Respiratory arrest	407.23	50.65	118	2408	5721	1738534
Coma	369.13	50.65	115	2411	7147	1737108
Cardiac arrest	362.01	50.65	138	2388	15792	1728463
Intentional overdose	350.49	50.65	112	2414	7558	1736697
Serotonin syndrome	342.04	50.65	88	2438	2700	1741555
Cardio-respiratory arrest	321.51	50.65	110	2416	9183	1735072
Electrocardiogram QRS complex prolonged	315.56	50.65	65	2461	710	1743545
Confusional state	267.79	50.65	121	2405	21157	1723098
Suicide attempt	245.73	50.65	85	2441	7296	1736959
Poisoning	229.70	50.65	63	2463	2469	1741786
Agitation	198.64	50.65	81	2445	10945	1733310
Drug interaction	182.46	50.65	102	2424	27856	1716399
Electrocardiogram QT prolonged	169.51	50.65	60	2466	5485	1738770
Intentional product misuse	163.64	50.65	63	2463	7295	1736960
Death	159.17	50.65	146	2380	87297	1656958
Depressed level of consciousness	148.54	50.65	57	2469	6535	1737720
Sedation	127.70	50.65	43	2483	3374	1740881
Drug hypersensitivity	122.93	50.65	64	2462	15071	1729184
Fall	121.76	50.65	78	2448	27136	1717119
Somnolence	116.86	50.65	64	2462	16675	1727580
Tachycardia	115.87	50.65	58	2468	12570	1731685
Loss of consciousness	112.53	50.65	60	2466	14815	1729440
Unresponsive to stimuli	111.30	50.65	42	2484	4587	1739668
Foetal exposure during pregnancy	101.70	50.65	43	2483	6316	1737939
Disturbance in attention	96.66	50.65	37	2489	4197	1740058
Drug ineffective	95.44	50.65	96	2430	63705	1680550
Delirium	95.05	50.65	41	2485	6321	1737934
Respiratory depression	94.79	50.65	31	2495	2216	1742039
Mydriasis	92.94	50.65	27	2499	1297	1742958
Hallucination	91.36	50.65	43	2483	8127	1736128
Accidental overdose	90.10	50.65	35	2491	4129	1740126
Cardiotoxicity	86.19	50.65	23	2503	805	1743450
Poisoning deliberate	85.80	50.65	23	2503	819	1743436
Brugada syndrome	84.48	50.65	18	2508	232	1744023
Generalised tonic-clonic seizure	83.97	50.65	33	2493	4013	1740242
Seizure	82.46	50.65	55	2471	20386	1723869
Hypotension	78.97	50.65	62	2464	29592	1714663
Hyponatraemia	72.76	50.65	38	2488	8962	1735293
Ventricular tachycardia	71.92	50.65	29	2497	3769	1740486
Aggression	70.60	50.65	36	2490	8079	1736176
Depression	69.96	50.65	46	2480	16623	1727632
Delusion of replacement	68.78	50.65	11	2515	21	1744234
Acute respiratory distress syndrome	66.84	50.65	27	2499	3524	1740731
Exposure via ingestion	66.57	50.65	18	2508	662	1743593
Substance abuse	63.99	50.65	19	2507	984	1743271
Pulmonary congestion	60.66	50.65	21	2505	1784	1742471
Quality of life decreased	60.44	50.65	16	2510	542	1743713
Arrhythmia	59.12	50.65	29	2497	5987	1738268
Myoclonus	55.74	50.65	21	2505	2274	1741981
Nervous system disorder	54.37	50.65	21	2505	2433	1741822
Heart rate increased	54.05	50.65	28	2498	6482	1737773
Pulmonary oedema	53.74	50.65	28	2498	6558	1737697
Constipation	52.45	50.65	37	2489	14963	1729292
Arteriosclerosis coronary artery	52.14	50.65	19	2507	1873	1742382
Migraine	51.99	50.65	20	2506	2291	1741964
Dyskinesia	51.75	50.65	23	2503	3796	1740459

Pharmacologic Action:

Source	Code	Description
ATC	N06AA09	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
ATC	N06CA01	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION Antidepressants in combination with psycholeptics
MeSH PA	D018663	Adrenergic Agents
FDA EPC	N0000175752	Tricyclic Antidepressant
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitor
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018689	Sensory System Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Depressive disorder	indication	35489007
Mixed anxiety and depressive disorder	indication	231504006
Posttraumatic stress disorder	off-label use	47505003	DOID:2055
Bulimia nervosa	off-label use	78004001
Fibromyalgia	off-label use	203082005	DOID:631
Neuropathic pain	off-label use	247398009
Migraine Prevention	off-label use
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Sinus tachycardia	contraindication	11092001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Disorder of lung	contraindication	19829001	DOID:850
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hyperactive behavior	contraindication	44548000
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Chronic idiopathic constipation	contraindication	82934008
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Kidney disease	contraindication	90708001	DOID:557
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Hypoalbuminemia	contraindication	119247004
Acute disease of cardiovascular system	contraindication	128487001
Bipolar affective disorder, current episode manic	contraindication	191618007
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Syncope	contraindication	271594007
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Severe chronic obstructive pulmonary disease	contraindication	313299006
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Myocardial infarction in recovery phase	contraindication	418044006
Porphyria	contraindication	418470004
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.66	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Kd	8.37		WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	7.46		WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.88		DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	8.07		DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	8.25		DRUG MATRIX
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN		IC50	5.80		CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.21		CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.77		CHEMBL
Sodium channel protein type 9 subunit alpha	Ion channel	Q15858	SCN9A_HUMAN		IC50	6		CHEMBL
Sodium channel protein type 2 subunit alpha	Ion channel	Q99250	SCN2A_HUMAN		IC50	5.51		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	8.10		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.96		WOMBAT-PK
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.85		WOMBAT-PK
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	8.14		WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		IC50	8		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		IC50	7.90		WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.05		WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.40		WOMBAT-PK
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.05		WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		IC50	6.25		WOMBAT-PK
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.59		WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.80		WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.14		WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.89		WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	8.10		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	7.83		WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		IC50	6.80		WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.30		WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	6.77		WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.69		WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	6.40		WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.72		WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.71		WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5		WOMBAT-PK
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		IC50	4.22		CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		IC50	6		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT	ANTAGONIST	Ki	8.10		IUPHAR
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT	ANTAGONIST	Ki	8.40		IUPHAR
5-hydroxytryptamine receptor 7	GPCR		5HT7R_MOUSE	ANTAGONIST	Ki	6.40		IUPHAR
G protein-activated inward rectifier potassium channel 2	Ion channel		KCNJ6_MOUSE	BLOCKER	IC50	4		IUPHAR
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.38		DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.77		DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		IC50	5.07		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	10.70		CHEMBL
Transporter	Transporter		Q9WTR4_RAT		IC50	5.60		CHEMBL
Muscarinic acetylcholine receptor	GPCR		ACM1_RAT ACM2_RAT ACM3_RAT ACM4_RAT ACM5_RAT		IC50	6.52		CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	10.70		CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.20		IUPHAR
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.70		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	ANTAGONIST	Ki	7		IUPHAR

External reference:

ID	Source
D000639	MESH_DESCRIPTOR_UI
4019607	VUID
N0000147702	NUI
C0002600	UMLSCUI
D00809	KEGG_DRUG
1806D8D52K	UNII
976	INN_ID
549-18-8	SECONDARY_CAS_RN
40589005	SNOMEDCT_US
4019607	VANDF
704	RXNORM
372726002	SNOMEDCT_US
d00146	MMSL
004600	NDDF
CHEBI:2666	CHEBI
CHEMBL629	ChEMBL_ID
DB00321	DRUGBANK_ID
TP0	PDB_CHEM_ID
200	IUPHAR_LIGAND_ID
2160	PUBCHEM_CID
CHEMBL1200964	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0042	TABLET, FILM COATED	10 mg	ORAL	ANDA	13 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0073	TABLET, FILM COATED	50 mg	ORAL	ANDA	13 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0211	TABLET, FILM COATED	14 mg	ORAL	ANDA	14 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0277	TABLET, FILM COATED	27.98 mg	ORAL	ANDA	14 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0330	TABLET, FILM COATED	10 mg	ORAL	ANDA	13 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0442	TABLET, FILM COATED	25 mg	ORAL	ANDA	13 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0574	TABLET, FILM COATED	25 mg	ORAL	ANDA	13 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2610	TABLET, FILM COATED	10 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2625	TABLET, FILM COATED	25 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2650	TABLET, FILM COATED	50 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2675	TABLET, FILM COATED	75 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2685	TABLET, FILM COATED	100 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2695	TABLET, FILM COATED	150 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0463-6351	TABLET, FILM COATED	25 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0463-6352	TABLET, FILM COATED	50 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0463-6354	TABLET, FILM COATED	100 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2212	TABLET, FILM COATED	10 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2213	TABLET, FILM COATED	25 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2214	TABLET, FILM COATED	50 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2215	TABLET, FILM COATED	75 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2216	TABLET, FILM COATED	100 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2217	TABLET, FILM COATED	150 mg	ORAL	ANDA	16 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-0828	TABLET, FILM COATED	10 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-0829	TABLET, FILM COATED	25 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-0830	TABLET, FILM COATED	50 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-1486	TABLET, FILM COATED	10 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-1487	TABLET, FILM COATED	25 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-1488	TABLET, FILM COATED	50 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-1489	TABLET, FILM COATED	75 mg	ORAL	ANDA	15 sections
Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-1490	TABLET, FILM COATED	100 mg	ORAL	ANDA	15 sections